Vivus Plans Evamist NDA In Q4 2006, But Obesity Combo Qnexa Is Top Priority
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.
You may also be interested in...
Vivus/KV EvaMist approval
FDA approves Vivus' metered-dose topical estradiol spray EvaMist to treat moderate to severe vasomotor symptoms due to menopause. The July 27 approval triggers a $140 million payment to Vivus from KV Pharmaceutical, which will market the drug with its more than 280-strong sales force. Vivus received a $10 million up-front payment and is eligible to get more money based on sales milestones. The firm is touting EvaMist's safety profile, but will be competing in a crowded transdermal estradiol market with close competitors Esprit Pharma's Estrasorb, Ascend's EstroGel and BioSante's Elestrin. Vivus is also developing an obesity combo agent, Qnexa (1Pharmaceutical Approvals Monthly September 2006, p. 11)...
J&J Weighs Topamax Controlled-Release After Dropping Obesity Program
J&J weighs Topamax controlled-release formulation after dropping obesity program. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says. Topiramate CR was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011